Log in

Relevant bibliographies by topics / Dalfampridine / Journal articles

To see the other types of publications on this topic, follow the link: Dalfampridine.

Journal articles on the topic 'Dalfampridine'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Dalfampridine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Satchidanand, Nikhil, Allison Drake, A. Smerbeck, et al. "Dalfampridine benefits ambulation but not cognition in multiple sclerosis." Multiple Sclerosis Journal 26, no. 1 (2018): 91–98. http://dx.doi.org/10.1177/1352458518815795.

Full text

Abstract:

Background: Impaired cognition and ambulation are common in multiple sclerosis (MS). Dalfampridine is the first Food and Drug Administration (FDA)–approved medication to treat impaired ambulation in MS. Dalfampridine may benefit patients with cognitive impairment, given its effects on saltatory conduction and the association between cognitive and motor function. Objective: To examine the effects of dalfampridine on cognition in MS. To determine if the anticipated improved cognition is grounded in dalfampridine’s effects on ambulation. Methods: Adults with MS were randomized to dalfampridine (

APA, Harvard, Vancouver, ISO, and other styles

2

Farag, Amanda, and Allison Averill. "Dalfampridine." American Journal of Physical Medicine & Rehabilitation 92, no. 7 (2013): 635–36. http://dx.doi.org/10.1097/phm.0b013e31826ed8ea.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Yapundich, Robert, Angela Applebee, Francois Bethoux, et al. "Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis." International Journal of MS Care 17, no. 3 (2015): 138–45. http://dx.doi.org/10.7224/1537-2073.2014-040.

Full text

Abstract:

Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients were randomized to double-blind treatment with twice-daily dalfampridine-ER tablets, 5 mg (n = 144) or 10 mg (n = 143), or placebo (n = 143) for 4 weeks. Primary efficacy endpoint was change from baseline walking speed by the Timed 25-Foot Walk 3 to 4 hours after the last dose. At 40% of sites, 2-week change from baseline walking distance was measured

APA, Harvard, Vancouver, ISO, and other styles

4

Goodman, Andrew D., Francois Bethoux, Theodore R. Brown, et al. "Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials." Multiple Sclerosis Journal 21, no. 10 (2015): 1322–31. http://dx.doi.org/10.1177/1352458514563591.

Full text

Abstract:

Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking speed relative to placebo in patients with multiple sclerosis (MS). Objectives: Evaluation of long-term safety and efficacy of dalfampridine-ER in open-label extensions (MS-F203EXT, MS-F204EXT). Methods: Patients received dalfampridine-ER 10 mg twice daily; and had Timed 25-Foot Walk (T25FW) assessments at 2, 14 and 26 weeks, and then every 6 mont

APA, Harvard, Vancouver, ISO, and other styles

5

Cameron, Michelle H., Mary Fitzpatrick, Shannon Overs, Charles Murchison, Jane Manning, and Ruth Whitham. "Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study." Multiple Sclerosis Journal 20, no. 6 (2013): 733–38. http://dx.doi.org/10.1177/1352458513507356.

Full text

Abstract:

Background: In short-term trials, dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS). The tolerability and effects of dalfampridine-ER in clinical practice have not been reported. Objectives: The objective of this paper is to determine the clinical tolerability and effects of dalfampridine on walking and community participation. Methods: All patients at the Portland VA Medical Center prescribed dalfampridine-ER over one year completed the Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale-12 (MSWS-12), Two-Minute Timed Walk (2MTW), and Communi

APA, Harvard, Vancouver, ISO, and other styles

6

Fjeldstad, Cecilie, Gustavo Suárez, Michael Klingler, Herbert R. Henney, Adrian L. Rabinowicz, and Gabriel Pardo. "Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis." International Journal of MS Care 17, no. 6 (2015): 275–83. http://dx.doi.org/10.7224/1537-2073.2014-036.

Full text

Abstract:

Background: Dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS), as demonstrated by walking speed improvement. This exploratory study evaluated treatment effects of dalfampridine-ER on gait, balance, and walking through treatment withdrawal and reinitiation. Methods: Dalfampridine-ER responders, based on Timed 25-Foot Walk (T25FW) assessment before study entry, were included in this open-label, three-period, single-center study. Period 1: on-drug evaluations performed at screening and 1 week after screening. Period 2: dalfampridine-ER withdrawal and off-

APA, Harvard, Vancouver, ISO, and other styles

7

Plummer, Prudence. "Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis." International Journal of MS Care 18, no. 3 (2016): 105–15. http://dx.doi.org/10.7224/1537-2073.2014-114.

Full text

Abstract:

Background: Research has not yet compared the treatment effects of dalfampridine with traditional rehabilitation of gait impairments in multiple sclerosis (MS). The purpose of this review was to critically appraise the evidence for dalfampridine and gait training for increasing gait speed in people with MS. Methods: A systematic search of the research literature was conducted. Consideration was given to only randomized controlled trials (RCTs), systematic reviews, and meta-analyses. For selection of gait training studies, only studies involving task-specific gait training interventions and mea

APA, Harvard, Vancouver, ISO, and other styles

8

De Giglio, Laura, Francesca De Luca, Flavia Gurreri, et al. "Effect of dalfampridine on information processing speed impairment in multiple sclerosis." Neurology 93, no. 8 (2019): e733-e746. http://dx.doi.org/10.1212/wnl.0000000000007970.

Full text

Abstract:

ObjectiveTo test a possible benefit of dalfampridine on information processing speed (IPS), a key function for cognitive impairment (CogIm) in multiple sclerosis (MS).MethodsIn this randomized, double-blind, placebo-controlled trial, we included patients with a score on the Symbol Digit Modalities Test (SDMT) under the 10th percentile of the reference value. Patients were randomized in a 2:1 ratio to receive dalfampridine 10 mg or placebo twice daily for 12 weeks. They underwent a comprehensive neuropsychological evaluation at screening (T0), at the end of treatment (T1), and after a 4-week fo

APA, Harvard, Vancouver, ISO, and other styles

9

Klineova, Sylvia, Rebecca Farber, Joshua Friedman, Colleen Farrell, Fred D. Lublin, and Stephen Krieger. "Objective and subjective measures of dalfampridine efficacy in clinical practice." Multiple Sclerosis Journal - Experimental, Translational and Clinical 4, no. 3 (2018): 205521731878674. http://dx.doi.org/10.1177/2055217318786742.

Full text

Abstract:

Background Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patient-reported ambulation inventory. Methods Chart review identified patients with multiple sclerosis for whom dalfampridine was prescribed. T25FW data were extracted from medical records. Participants completed a dalfampridine-specific version of the multiple sclerosis walking scale (dMSWS-12) to asses

APA, Harvard, Vancouver, ISO, and other styles

10

Chwieduk, Claudine M., and Gillian M. Keating. "Dalfampridine Extended Release." CNS Drugs 24, no. 10 (2010): 883–91. http://dx.doi.org/10.2165/11205910-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Malamud, Emily, and Scott I. Otallah. "Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2." Child Neurology Open 9 (January 2022): 2329048X2210754. http://dx.doi.org/10.1177/2329048x221075447.

Full text

Abstract:

Episodic ataxia type 2 (EA2) is a rare autosomal dominant disorder associated with mutations of the CACNA1A gene. 1 Because there is no curative therapy available, EA2 is typically managed symptomatically. First line treatment has typically been with acetazolamide. 2 Dalfampridine has also been noted to decrease the frequency and duration of ataxic attacks in patients ranging in age from adolescence through adulthood. 3 , 4 The efficacy and dosing of dalfampridine has not yet been studied in younger pediatric populations. The lack of published experience in younger children can and has led to

APA, Harvard, Vancouver, ISO, and other styles

12

Traynor, Kate. "Dalfampridine approved for MS." American Journal of Health-System Pharmacy 67, no. 5 (2010): 335. http://dx.doi.org/10.2146/news100015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Goodman, A. D., and M. Hyland. "Dalfampridine in multiple sclerosis." Drugs of Today 46, no. 9 (2010): 635. http://dx.doi.org/10.1358/dot.2010.46.9.1499027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Raffel, JB, O. Malik, and RS Nicholas. "Assessing dalfampridine efficacy in the physician’s office." Multiple Sclerosis Journal 20, no. 1 (2013): 24–26. http://dx.doi.org/10.1177/1352458513489601.

Full text

Abstract:

Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients. For the neurologist working in an everyday physician’s office, a key question arises: How to distinguish the few who experience a meaningful clinical benefit, from the many who do not? This question has not yet been adequately addressed in the available literature.

APA, Harvard, Vancouver, ISO, and other styles

15

Miller, Aaron, Amy Perrin Ross, and James Gilbart. "Dalfampridine Extended Release Tablets—Clinical Need and Use." US Neurology 06, no. 02 (2010): 76. http://dx.doi.org/10.17925/usn.2010.06.02.76.

Full text

Abstract:

Walking impairment is one of the most serious and frequent problems reported by multiple sclerosis (MS) patients. Treatments to restore walking ability are an unmet clinical need. Dalfampridine, a potassium channel blocker, is the first US Food and Drug Administration (FDA)-approved drug to be indicated specifically to improve walking in patients with MS. In clinical trials the drug showed improved walking speeds, demonstrating efficacy in all four types of MS. In phase III trials, dalfampridine provided significant benefits to 35–43% of treated patients. Therefore, it will be critical to mana

APA, Harvard, Vancouver, ISO, and other styles

16

Prosperini, Luca, Costanza Giannì, Deborah Fortuna, Maria Rita Marchetti, and Carlo Pozzilli. "Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis." Multiple Sclerosis International 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/802307.

Full text

Abstract:

We report a 14-week post-marketing experience on 20 patients with multiple sclerosis (MS) who started prolonged-release (PR) oral dalfampridine 10 mg twice daily according to European Medicine Agency criteria. They underwent serial static posturography assessments and the dizziness handicap inventory (DHI) to investigate whether PR dalfampridine could impact standing balance and self-reported perception of balance. The incidence of accidental falls per person per month was also recorded throughout the study. Eight (40%) patients, who had a relevant improvement in walking speed, were defined as

APA, Harvard, Vancouver, ISO, and other styles

17

M., Kelani Khadiga, Wafaa Nassar Ahmed M., Wael Talaat, and Samir Morshedy. "Comparative Chomatographic Study for Determination of Dalfampridine and its Derivative in Pharmaceutical Formulations." Der Pharma Chemica 13, no. 1 (2021): 8. https://doi.org/10.5281/zenodo.13643967.

Full text

Abstract:

Two sensitive and precise methods were developed and validated for simultaneous estimation of dalfampridine with its oxidative degradation in pharmaceutical formulations without noticeable interference. Among the techniques adopted were chromatography [coupled TLC-densitometry and HPLC]. Method I: chromatographic separation a Spheri-5 RP C8 (220 X 4.6 X 5μm particle size) column was used in addition to the mobile phase [acetonitrile and 0.05 M KH2PO4 - (pH=5), (65: 35 v /v)], with a flow rate of (1ml.min−1) by detection (UV) at 298 nm. Method II: Densitometric separation of the drugs

APA, Harvard, Vancouver, ISO, and other styles

18

Fil, Laura, Payal Sud, and Steven Sattler. "A Massive Overdose of Dalfampridine." Western Journal of Emergency Medicine 16, no. 7 (2015): 1177–79. http://dx.doi.org/10.5811/westjem.2015.8.26127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rabinowicz, Adrian L., and Enrique J. Carrazana. "Clarification of Dalfampridine Labeled Indications." Journal of Managed Care Pharmacy 18, no. 2 (2012): 156. http://dx.doi.org/10.18553/jmcp.2012.18.2.156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Belavic, Jennifer M. "Dalfampridine (Ampyra) for multiple sclerosis." Nurse Practitioner 35, no. 11 (2010): 7–9. http://dx.doi.org/10.1097/01.npr.0000389051.00652.80.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sahraian, M. A., A. H. Maghzi, M. Etemadifar, and A. Minagar. "Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis." Journal of Central Nervous System Disease 3 (January 2011): JCNSD.S4868. http://dx.doi.org/10.4137/jcnsd.s4868.

Full text

Abstract:

Multiple sclerosis (MS) is a progressive immune-mediated neurodegenerative disease of human central nervous system (CNS), which causes irreversible disability in young adults. The cause and cure for MS remain unknown. Pathophysiology of MS includes two arms: inflammatory demyelination and neurodegeneration. The inflammatory demyelination of MS which is mainly promoted by a massive activation of the immune system against putative CNS antigen(s) leads to loss of oligodendrocyte/myelin complex which slows down or halts impulse conduction in denuded axons. Practically, loss of myelin significantly

APA, Harvard, Vancouver, ISO, and other styles

22

Schwartz, Kateryna, Nicholas F. Wymbs, Hwa Huang, et al. "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis." Multiple Sclerosis Journal - Experimental, Translational and Clinical 3, no. 4 (2017): 205521731774014. http://dx.doi.org/10.1177/2055217317740145.

Full text

Abstract:

Background Dalfampridine has the potential to be effective in patients with transverse myelitis (TM) as this rare disorder shares some clinical and pathogenic similarities with multiple sclerosis. Methods This is a randomized, double-blind, placebo-controlled crossover study of dalfampridine extended-release (D-ER, Ampyra®). Sixteen adult study participants with monophasic TM confirmed by MRI were enrolled if their baseline timed 25-foot walking speed was between 5 and 60 seconds. Participants were randomized to receive 10 mg twice-daily doses of either D-ER or placebo control for eight weeks,

APA, Harvard, Vancouver, ISO, and other styles

23

Hussar, Daniel A., and Jessica Kaczinski. "New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA." Journal of the American Pharmacists Association 50, no. 3 (2010): 436–39. http://dx.doi.org/10.1331/japha.2010.10520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Panicucci, Emilie, Mikael Cohen, Veronique Bourg, Fanny Rocher, Pierre Thomas, and Christine Lebrun. "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine." Multiple Sclerosis Journal 25, no. 4 (2018): 618–21. http://dx.doi.org/10.1177/1352458518790379.

Full text

Abstract:

Background: Dalfampridine extended release (DAL) is a broad-spectrum voltage-gated potassium channel blocker that is indicated in multiple sclerosis to improve the nerve conduction of demyelinated axons. Seizures are a known side effect of DAL, which is contraindicated in patients with a history of epilepsy. Objective: Three cases of multiple sclerosis (MS) with de novo convulsive status epilepticus (CSE) probably related to dalfampridine administration are described. Methods: No patients had a history of seizures or renal impairment. Biological tests were normal. A brain magnetic resonance im

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "FDA warns of seizure risk with dalfampridine." Reactions Weekly &NA;, no. 1412 (2012): 2. http://dx.doi.org/10.2165/00128415-201214120-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Gleason, Patrick P., Jill Phillips, Beckie A. Fenrick, Ana Delgado-Riley, and Catherine I. Starner. "Dalfampridine Prior Authorization Program: A Cohort Study." Journal of Managed Care Pharmacy 19, no. 1 (2013): 18–25. http://dx.doi.org/10.18553/jmcp.2013.19.1.18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sumowski, James F., and Nils Muhlert. "Dalfampridine improves slowed processing speed in MS." Neurology 93, no. 8 (2019): 325–26. http://dx.doi.org/10.1212/wnl.0000000000007964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Korsen, Melanie, Rhina Kunz, Ulf Schminke, Uwe Runge, Thomas Kohlmann, and Alexander Dressel. "Dalfampridine effects on cognition, fatigue, and dexterity." Brain and Behavior 7, no. 1 (2016): e00559. http://dx.doi.org/10.1002/brb3.559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Plummer, Prue, Alexis A. Williams, Corinne J. Bohling, et al. "Combining Dalfampridine with Physical Therapy May Improve Treatment Effects in Dalfampridine Non-responders with Multiple Sclerosis: A Case Study." Archives of Physical Medicine and Rehabilitation 97, no. 10 (2016): e62. http://dx.doi.org/10.1016/j.apmr.2016.08.189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Mayer, Lori, Tina Warring, Stephanie Agrella, Helen L. Rogers, and Edward J. Fox. "Effects of Functional Electrical Stimulation on Gait Function and Quality of Life for People with Multiple Sclerosis Taking Dalfampridine." International Journal of MS Care 17, no. 1 (2015): 35–41. http://dx.doi.org/10.7224/1537-2073.2013-033.

Full text

Abstract:

Background: Multiple sclerosis (MS) can adversely affect gait, causing gait slowing, loss of balance, decreased functional mobility, and gait deficits, such as footdrop. Current treatments for gait dysfunction due to MS are pharmacologic, using dalfampridine, or orthotic, using an ankle-foot orthosis. Functional electrical stimulation (FES) to the fibular nerve stimulates active dorsiflexion and provides an alternative treatment for gait dysfunction caused by footdrop. The objective of this study was to determine the effect of FES on gait function and the impact of MS on walking and quality of

APA, Harvard, Vancouver, ISO, and other styles

31

Mhaskey, Yukta K., Dr Vikrant P. Wankhade, Aditi V. Tikait, Dr Sandeep C. Atram, Nishant N. Bobade, and Dr S. D. Pande. "Formulation and Evaluation of Delayed Release Coated Tablet of Dalfampridine for the Treatment of Multiple Sclerosis." Asian Journal of Pharmaceutical Research and Development 12, no. 4 (2024): 20–27. http://dx.doi.org/10.22270/ajprd.v12i4.1436.

Full text

Abstract:

The study aimed to develop delayed release coated tablets of Dalfampridine for treating multiple sclerosis. Dalfampridine core tablets were prepared using wet granulation method with various excipients. Pre-compression parameters and flow characteristics were evaluated to ensure smooth tablet production. Post-compression studies included weight variation, thickness, hardness, friability, drug content, and In-vitro drug release. Coating was applied to the core table formulation using a 5% coating solution consisting of Eudragit L100-55, PEG-600, talc, color concentrate, IPA, and acetone. Coatin

APA, Harvard, Vancouver, ISO, and other styles

32

Schniepp, Roman, Veronika Jakl, Max Wuehr, et al. "Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report." Multiple Sclerosis Journal 19, no. 4 (2012): 506–8. http://dx.doi.org/10.1177/1352458512461394.

Full text

Abstract:

The reversible potassium channel blocker 4-aminopyridine is effective in the treatment of numerous cerebellar dysfunctions, such as episodic ataxia type 2 and downbeat nystagmus syndrome. In 2011, its sustained release form, dalfampridine, was admitted in Europe for the treatment of walking difficulties in patients with multiple sclerosis (MS). Here we report the case of a 44-year old patient with a progressive MS whose upper limb tremor was markedly reduced under treatment with 4-aminopyridine, as documented in a Tremor Activities of Daily Living questionnaire and in the 9-Hole Peg test. Hand

APA, Harvard, Vancouver, ISO, and other styles

33

Aschenbrenner, Diane S. "Risk of Seizure with the MS Drug Dalfampridine." AJN, American Journal of Nursing 112, no. 12 (2012): 20. http://dx.doi.org/10.1097/01.naj.0000423498.23146.3d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Uygunoglu, Ugur, Aysegul Gunduz, Melih Tutuncu, Mehmet Ali Akalin, Sabahattin Saip, and Aksel Siva. "The Effects of Dalfampridine on Hereditary Spastic Paraparesis." European Neurology 76, no. 3-4 (2016): 152–53. http://dx.doi.org/10.1159/000449375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Moster, Mark L., Robert C. Sergott, and Benjamin E. Leiby. "Dalfampridine Treatment in Nonarteritic Anterior Ischemic Optic Neuropathy." Journal of Neuro-Ophthalmology 37, no. 3 (2017): 348–49. http://dx.doi.org/10.1097/wno.0000000000000523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Haut, Sheryl R., E. Jay Bienen, and Aaron Miller. "Clinical overview of the seizure risk of dalfampridine." Expert Opinion on Drug Safety 11, no. 4 (2012): 651–57. http://dx.doi.org/10.1517/14740338.2012.697896.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Blight, Andrew R. "Treatment of walking impairment in multiple sclerosis with dalfampridine." Therapeutic Advances in Neurological Disorders 4, no. 2 (2011): 99–109. http://dx.doi.org/10.1177/1756285611403960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Serra, A., M. M. Skelly, J. B. Jacobs, M. F. Walker, and J. A. Cohen. "Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine." Neurology 83, no. 2 (2014): 192–94. http://dx.doi.org/10.1212/wnl.0000000000000567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Espejo, Carmen, and Xavier Montalban. "Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation." Clinical Immunology 142, no. 1 (2012): 84–92. http://dx.doi.org/10.1016/j.clim.2011.06.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Béreau, Matthieu, Mathieu Anheim, Jean-Baptiste Chanson, et al. "Dalfampridine in hereditary spastic paraplegia: a prospective, open study." Journal of Neurology 262, no. 5 (2015): 1285–88. http://dx.doi.org/10.1007/s00415-015-7707-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Claassen, Jens, Katharina Feil, Stanislav Bardins, et al. "Dalfampridine in patients with downbeat nystagmus—an observational study." Journal of Neurology 260, no. 8 (2013): 1992–96. http://dx.doi.org/10.1007/s00415-013-6911-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

McDonald, Sarah, and Jennifer N. Clements. "Dalfampridine: A new agent for symptomatic management of multiple sclerosis." American Journal of Health-System Pharmacy 68, no. 24 (2011): 2335–40. http://dx.doi.org/10.2146/ajhp110134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Tang, Junger, and Moses Rodriguez. "Dalfampridine for the treatment of ambulatory impairment in multiple sclerosis." Future Neurology 5, no. 5 (2010): 637–43. http://dx.doi.org/10.2217/fnl.10.52.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Ruck, T., S. Bittner, O. J. Simon, et al. "Long-term effects of dalfampridine in patients with multiple sclerosis." Journal of the Neurological Sciences 337, no. 1-2 (2014): 18–24. http://dx.doi.org/10.1016/j.jns.2013.11.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Thaera, Greg M., Dean M. Wingerchuk, and Jonathan L. Carter. "Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis." Multiple Sclerosis and Related Disorders 3, no. 1 (2014): 107–9. http://dx.doi.org/10.1016/j.msard.2013.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Thaera, G., D. Wingerchuk, and J. Carter. "Trigeminal Neuralgia with Initation of Dalfampridine for Multiple Sclerosis (P06.177)." Neurology 78, Meeting Abstracts 1 (2012): P06.177. http://dx.doi.org/10.1212/wnl.78.1_meetingabstracts.p06.177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lugaresi, Alessandra. "Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis." Expert Opinion on Drug Metabolism & Toxicology 11, no. 2 (2014): 295–306. http://dx.doi.org/10.1517/17425255.2015.993315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Amol, ghare, Gondkar Sheetal, and Bachhav Rishikesh. "Formulation Development and Evaluation Of Wax Incorporated Floating Beads Of Dalfampridine." Int. J. in Pharm. Sci. 1, no. 2 (2022): 104——111. https://doi.org/10.5281/zenodo.6257256.

Full text

Abstract:

In this study, the Dalfampridine multi-unit sustained release gastric drug delivery system was developed from a purely aqueous medium, avoiding the use of any organic solvents, thereby releasing the drug over a short period of time. time. The emulsion gelation technique is used to prepare the beads. Edible oil pearls are made by mixing and homogenizing olive oil and water containing pectin and molten wax, then extruding them into a solution of calcium chloride. The effects of carnauba wax on smoking efficacy, variation in delay, morphology, and drug release have been studied. Carnauba wax was

APA, Harvard, Vancouver, ISO, and other styles

49

Caggiano, Anthony, Andrew Blight, and Tom J. Parry. "Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat." Journal of Drug Assessment 2, no. 1 (2013): 72–80. http://dx.doi.org/10.3109/21556660.2013.794143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

de Gusmao, Claudio M., Melissa R. Ortega, and Douglas M. Wallace. "Status Epilepticus Associated With Dalfampridine in a Patient With Multiple Sclerosis." Journal of Neuropsychiatry and Clinical Neurosciences 24, no. 4 (2012): E47—E48. http://dx.doi.org/10.1176/appi.neuropsych.11110338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!